U.S. FDA grants Fast Track Designation to REQORSA® in Combination with Tecentriq® for the Treatment of Small Cell Lung Cancer July 5, 2023
Impact Therapeutics Entered into Global Partnership with Eikon Therapeutics to Develop and Commercialize PARP1 Selective Inhibitors June 6, 2023
Lurbinectedin “Named Patient Program” for Small-Cell Lung Cancer launched in Hong Kong January 17, 2023
Merck Advances Development Programs in Oncology Focusing on Novel Mechanisms and Pathways June 13, 2022
